Antibody-based NBEs
NBE-Therapeutics LLC
Incorporated
18.04.2012Headquarters
BaselSupport
BE-Therapeutics is a privately-owned Swiss biotech company based in Basel and founded in 2012 with the vision of developing next-generation immune-stimulatory antibody drug conjugate (iADCTM) products. NBE advances its products to clinical proof of concept with the goal of improving treatment options for cancer patients. The company leverages proprietary platforms covering all aspects of ADC development: its Transpo-mAb DisplayTM technology for antibody discovery, its SMAC-TechnologyTM for site-specific payload conjugation of toxins to antibodies and a novel highly effective and immune-stimulatory anthracycline-based toxin platform.
News
"You cannot do it alone" — Interview with Christian Elias Schneider of the Innovation Office at the University of Basel (venturelab.swiss)
Ulf Grawunder: ‘If you have an idea that you feel passionate about, don’t let anyone stop you from creating a great company’ (venturelab.swiss)
Billion-Franc deal without champagne (TOP 100)
NBE Therapeutics makes a €1.18 billion exit (startupticker.ch)
Boehringer Ingelheim acquiring NBE-Therapeutics for €1.18 billion (venturelab.swiss)
NBE-Therapeutics launches first clinical trials (startupticker.ch)
Startups win strong and well-connected board members (startupticker.ch)
NBE-Therapeutics receives USD 25 million upfront payment (startupticker.ch)
An almost complete C-suite for Swiss startups (startupticker.ch)
Swiss Biotech Startup NBE-Therapeutics Closes a USD 22M Series C Financing Round (venturelab.swiss)
NBE-Therapeutics closes USD 22 million financing round (startupticker.ch)
SOTIO expands collaboration with NBE Therapeutics (startupticker.ch)
NOVO Holdings invests CHF 20 million in NBE Therapeutics (startupticker.ch)
NBE Therapeutics welcomes expert in clinical development of oncology drugs to its Board of directors (startupticker.ch)
NBE Therapeutics Raises CHF 20 Million in Series B Funding (startupticker.ch)
New partner and investor for NBE Therapeutics (startupticker.ch)
Financial support for NBE-Therapeutics’ R&D project (startupticker.ch)
NBE-Therapeutics closes CHF 3.0 Mio series A financing (startupticker.ch)
NBE-Therapeutics obtained CHF 600K SystemsX grant (startupticker.ch)
NBE-Therapeutics Announces Successful Validation of its Technology (startupticker.ch)
Milestones news
